Latest & greatest articles for fluconazole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluconazole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluconazole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluconazole

1. Fluconazole

Fluconazole Top results for fluconazole - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluconazole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

2. Yeast infection in pregnancy? Think twice about fluconazole

Yeast infection in pregnancy? Think twice about fluconazole Yeast infection in pregnancy? Think twice about fluconazole Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Yeast infection in pregnancy? Think twice about fluconazole View/ Open Date 2016-09 Format Metadata Abstract Yeast infection in pregnancy? Think twice (...) about fluconazole. This study's findings regarding the risk of miscarriage may mean it's time to forego fluconazole in favor of topical azoles as first-line treatment. Practice changer: Avoid prescribing oral fluconazole in early pregnancy because it is associated with a higher rate of spontaneous abortion than is topical azole therapy. STRENGTH OF RECOMMENDATION: B: Based on a large cohort study performed in Denmark. URI Part of Citation Journal of Family Practice, 65(9) 2016: 624-626 Collections

PURLS2017

3. Clinical effects of topical antifungal therapy in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial of intranasal fluconazole.

Clinical effects of topical antifungal therapy in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial of intranasal fluconazole. 27065776 2016 04 12 2016 04 12 2017 02 20 15 2016 EXCLI journal EXCLI J Clinical effects of topical antifungal therapy in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial of intranasal fluconazole. 95-102 10.17179/excli2015-678 Several studies have been in favor of fungi as a possible pathogenesis of chronic (...) rhinosinusitis (CRS); however, to date, there is no scientific consensus about the use of antifungal agents in disease management. The aim of the present study was to investigate the efficacy of intranasal fluconazole in improving disease symptoms and objective outcomes of patients with CRS. A randomized, double-blind, placebo-controlled study was conducted on 54 patients who were diagnosed with CRS and had not been responsive to routine medical treatments. They were randomly assigned to receive either

EXCLI journal2016 Full Text: Link to full Text with Trip Pro

4. Cohort study: Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus

Cohort study: Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus Article Text Women's health and midwifery Cohort study Oral fluconazole is often used during pregnancy

Evidence-Based Nursing (Requires free registration)2016

5. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial.

Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. IMPORTANCE: Invasive candidiasis in premature infants causes death and neurodevelopmental impairment. Fluconazole prophylaxis reduces candidiasis, but its effect on mortality and the safety of fluconazole are unknown. OBJECTIVE: To evaluate the efficacy and safety of fluconazole in preventing death or invasive candidiasis in extremely low-birth-weight infants. DESIGN, SETTING (...) , AND PATIENTS: This study was a randomized, blinded, placebo-controlled trial of fluconazole in premature infants. Infants weighing less than 750 g at birth (N = 361) from 32 neonatal intensive care units (NICUs) in the United States were randomly assigned to receive either fluconazole or placebo twice weekly for 42 days. Surviving infants were evaluated at 18 to 22 months corrected age for neurodevelopmental outcomes. The study was conducted between November 2008 and February 2013. INTERVENTIONS

JAMA2014

7. Fluconazole

Fluconazole USE OF FLUCONAZOLE IN PREGNANCY 0344 892 0909 USE OF FLUCONAZOLE IN PREGNANCY (Date of issue: May 2016 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Fluconazole is a triazole antifungal commonly used in the treatment (...) of candidiasis. Standard fluconazole therapy generally comprises a single 150mg oral dose. Fluconazole is not recommended for use during pregnancy. However, vaginal candidiasis is common in pregnancy, and as fluconazole is sometimes prescribed to treat candidiasis that has not responded to topical clotrimazole treatment, exposure during pregnancy is not uncommon. Where fluconazole use is considered necessary in pregnancy, the risks and benefits of treatment should be discussed with the patient to support

UK Teratology Information Service2014

8. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial.

Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. 24794367 2014 05 05 2014 05 16 2016 12 15 1538-3598 311 17 2014 May 07 JAMA JAMA Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial. 1742-9 10.1001/jama.2014.2624 Invasive candidiasis in premature infants causes death and neurodevelopmental impairment. Fluconazole prophylaxis reduces candidiasis, but its effect (...) on mortality and the safety of fluconazole are unknown. To evaluate the efficacy and safety of fluconazole in preventing death or invasive candidiasis in extremely low-birth-weight infants. This study was a randomized, blinded, placebo-controlled trial of fluconazole in premature infants. Infants weighing less than 750 g at birth (N = 361) from 32 neonatal intensive care units (NICUs) in the United States were randomly assigned to receive either fluconazole or placebo twice weekly for 42 days. Surviving

JAMA2014 Full Text: Link to full Text with Trip Pro

9. Use of oral fluconazole during pregnancy and the risk of birth defects.

Use of oral fluconazole during pregnancy and the risk of birth defects. BACKGROUND: Case reports suggest that long-term, high-dose fluconazole treatment for severe fungal infections during pregnancy causes a pattern of birth defects. It is unclear whether commonly used lower doses increase the risk of specific birth defects. METHODS: In a registry-based cohort of liveborn infants in Denmark, we evaluated first-trimester oral fluconazole exposure and the risk of birth defects overall (...) and of birth defects previously linked to azole antifungal agents. RESULTS: The majority of fluconazole-exposed pregnancies were in women who received common therapeutic doses of 150 mg (56% of pregnancies) or 300 mg (31%). Oral fluconazole exposure was not associated with an increased risk of birth defects overall (210 birth defects among 7352 fluconazole-exposed pregnancies [prevalence, 2.86%] and 25,159 birth defects among 968,236 unexposed pregnancies [prevalence, 2.60%]; adjusted prevalence odds ratio

NEJM2013

10. Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety

Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been (...) made for the HTA database. Citation CADTH. Fluconazole administration for the treatment of ductal yeast enfections: clinical effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2013 Authors' conclusions No health technology assessments, systematic reviews, randomized controlled trials, or non-randomized studies were identified regarding the clinical effectiveness or safety of fluconazole for the treatment of ductal

Health Technology Assessment (HTA) Database.2013

11. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials

Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials Mould (...) -active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials Ethier MC, Science M, Beyene J, Briel M, Lehrnbecher T, Sung L CRD summary Compared with fluconazole prophylaxis, mould-active prophylaxis significantly reduced the number of proven or probable invasive fungal infection, invasive aspergillosis and invasive fungal

DARE.2012

12. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in US patients with graft-versus-host disease

Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in US patients with graft-versus-host disease Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in US patients with graft-versus-host disease Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in US patients with graft-versus-host disease O'Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston AA (...) , Perfect JR, Papadopoulos G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of posaconazole versus fluconazole, for the prevention of invasive fungal infections, in patients with graft-versus-host

NHS Economic Evaluation Database.2012

13. Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin

Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin Blyth CC, Barzi F, Hale K, Isaacs D CRD summary The authors concluded that both fluconazole and nystatin prevented (...) of conference proceeding and previous reviews. Study selection Randomised controlled trials and quasi-randomised controlled trials that compared prophylactic antifungal therapy (fluconazole or nystatin) with placebo, no drug, another antifungal agent or antifungal dose regimen in very low birthweight infants (lower than 1,500g at birth) were eligible for inclusion. The primary outcome was incidence of fungal infections defined as isolation of fungus from a normally sterile site such as the blood

DARE.2012

14. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis

Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis Neoh CF, Liew D, Slavin M, Marriott D, Chen SC, Morrissey O, Stewart K, Kong DC Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the cost-effectiveness of anidulafungin versus fluconazole in the treatment of invasive candidiasis. The authors concluded that anidulafungin was cost-effective. The methods were adequate, and they and the results were sufficiently reported. Given the scope

NHS Economic Evaluation Database.2011

15. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants

Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants 20659937 2011 04 14 2011 06 24 2013 11 21 1468-2052 96 3 2011 May Archives of disease in childhood. Fetal and neonatal edition Arch. Dis. Child. Fetal Neonatal Ed. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low (...) birth weight infants. F164-8 10.1136/adc.2009.178996 Invasive fungal infections are a major cause of morbidity and mortality in preterm infants. The authors conducted the first prospective, randomised controlled trial of nystatin compared with fluconazole for the prevention of fungal colonisation and invasive fungal infection in very low birth weight (VLBW) neonates. During a 12-month period, all VLBW neonates were assigned randomly to receive nystatin (1 ml suspension, 100 000 U/ml, every 8 h

EvidenceUpdates2011

16. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis

Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis Posaconazole versus fluconazole or itraconazole (...) This study investigated the cost-effectiveness of posaconazole compared with fluconazole or itraconazole, for the prevention of invasive fungal infections, in adults with acute myeloid leukaemia or myelodysplasia who were receiving cytotoxic chemotherapy. The authors concluded that posaconazole was cost-effective and cost-saving, in cancer patients with prolonged neutropenia, in Canada. The methods and analyses were not entirely clear, and it is not clear that the authors’ conclusions are appropriate

NHS Economic Evaluation Database.2011

17. Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness

Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Fluconazole and pharmaceuticals without inactive ingredients for autism: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions The efficacy of antifungal agents for the treatment of autism has not been demonstrated in published clinical trials or observational studies

Health Technology Assessment (HTA) Database.2010

18. Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials

Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological (...) malignancies: a meta-analysis of randomized-controlled trials Wang J, Zhan P, Zhou R, Xu J, Shao X, Yang Y, Ouyang J CRD summary The review concluded that itraconazole resulted in significantly fewer episodes of fungal infections and invasive fungal infections than fluconazole, but also had a significantly higher risk of adverse effects in neutropenic patients with haematological malignancies. The authors' conclusions reflect the evidence presented and appear likely to be reliable. Authors' objectives

DARE.2010

19. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States (...) O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of posaconazole compared with fluconazole or itraconazole

NHS Economic Evaluation Database.2009

20. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials

Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials 18068146 2008 01 29 2008 02 19 2013 11 21 1097-6868 198 2 2008 Feb American journal of obstetrics and gynecology Am. J. Obstet. Gynecol. Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials. 153-60 (...) In this metaanalysis of randomized controlled trials (RCTs) we aimed to compare the in vivo and in vitro activity and the safety of per os itraconazole and fluconazole treatment of uncomplicated acute vaginal/vulvovaginal candidiasis in nonpregnant women. We used PubMed, Scopus, Web of Science, and Cochrane Library to identify the studies that were relevant to our metaanalysis RCTs. Six RCTs were included in this study that comprised 1092 enrolled patients with signs and symptoms of vaginal/vulvovaginal

EvidenceUpdates2008